Search Results

You are looking at 11 - 20 of 823 items for :

  • "metastases" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

Richard L. Theriault

OS Munro AJ Tannock IF . Bone metastases: pathophysiology and management policy . J Clin Oncol 1991 ; 9 : 509 – 524 . 7 Coleman RE Smith P Rubens RD . Clinical course and prognostic factors following bone recurrence from breast cancer

Full access

Jeffrey F. Moley

clinical cervical lymph node involvement is as high as 75%, and additional occult metastases may be present. 10 , 11 Clinical complaints, including respiratory difficulty, hoarseness, and dysphagia, are present in approximately 15% of patients with

Full access

Presenters: Douglas B. Johnson, Susan M. Swetter, April K.S. Salama, and Evan Wuthrick

Due to advances in immunotherapies and targeted agents, systemic therapies play an integral role in the up-front management of brain metastases in melanoma. At the same time, the choices for molecular testing have proliferated, particularly gene

Full access

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky, and Yoshiya Yamada

2003 to 2009. 1 At presentation, 25% of patients will demonstrate metastases, and 25% who undergo nephrectomy for localized disease will ultimately develop recurrent or metastatic tumor. 1 Targeted therapies directed against vascular endothelial

Full access

Barbara Dull, Andrew Linkugel, Julie A. Margenthaler, and Amy E. Cyr

recommended if signs or symptoms of possible distant metastases are present. Diagnostic chest CT is recommended if pulmonary symptoms are present at diagnosis. Several other societies have published similar guidelines. In 2012, ASCO addressed the rising

Full access

James J. Harding, Ghaith Abu-Zeinah, Joanne F. Chou, Dwight Hall Owen, Michele Ly, Maeve Aine Lowery, Marinela Capanu, Richard Do, Nancy E. Kemeny, Eileen M. O'Reilly, Leonard B. Saltz, and Ghassan K. Abou-Alfa

Bone metastases are common in hepatocellular carcinoma (HCC), occurring in 25.5% to 38.5% of patients with extrahepatic disease. 1 – 5 As such, major practice guidelines, including those of NCCN, acknowledge the need to evaluate for HCC bone

Full access

Larry K. Kvols, Kiran K. Turaga, Jonathan Strosberg, and Junsung Choi

J Gastroenterol 2005 ; 11 : 7676 – 7683 . 7 Sutcliffe R Maguire D Ramage J . Management of neuroendocrine liver metastases . Am J Surg 2004 ; 187 : 39 – 46 . 8 Pichlmayr R Weimann A Oldhafer KJ . Appraisal of

Full access

Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu

More than 20% of patients with cancer will develop brain metastases. 1 Primary malignancies most commonly associated with brain metastases are lung, breast, and gastrointestinal cancers and melanoma, constituting up to 80% of brain metastases. 1

Full access

Michelle C. Nguyen, Manisha H. Shah, David A. Liebner, Floor J. Backes, John Phay, and Lawrence A. Shirley

for melanoma metastases to the lung, liver, subcutaneous and peritoneal tissue, and lymph nodes. The objective response appears to be highest for smaller metastatic lesions and those to the lung, with the most variable responses seen in the liver. 11

Full access

Saber Amin, Michael Baine, Jane Meza, and Chi Lin

Background Brain metastases (BMs) are the most common intracranial malignancy, occurring in 20% to 40% of all patients with cancer. 1 Each year, >150,000 people are diagnosed with BMs in the United States. 2 The incidence rate of BMs is estimated